Standard Biotools Inc (LAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Standard Biotools Inc (LAB) has a cash flow conversion efficiency ratio of -0.083x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.60 Million) by net assets ($561.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Standard Biotools Inc (LAB) balance sheet quality index to measure how much of total assets are equity-financed.
Standard Biotools Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Standard Biotools Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check LAB cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Standard Biotools Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Standard Biotools Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing LabTech Instruments Co Ltd
SHG:688056
|
0.014x |
|
Pollard Banknote Limited
TO:PBL
|
0.007x |
|
Trifork Holding AG
CO:TRIFOR
|
0.035x |
|
Super Group Ltd.
JSE:SPG
|
0.109x |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
-0.191x |
|
HCK Capital Group Bhd
KLSE:7105
|
-0.259x |
|
CHEERWIN GRP. -0000002
F:1RQ
|
N/A |
|
Regal Asian Investments Ltd
AU:RG8
|
N/A |
Annual Cash Flow Conversion Efficiency for Standard Biotools Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of Standard Biotools Inc from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Standard Biotools Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $424.29 Million | $-74.35 Million | -0.175x | +42.38% |
| 2024-12-31 | $471.72 Million | $-143.45 Million | -0.304x | -204.01% |
| 2023-12-31 | $-148.05 Million | $-43.29 Million | 0.292x | -73.35% |
| 2022-12-31 | $-81.47 Million | $-89.37 Million | 1.097x | +335.52% |
| 2021-12-31 | $94.60 Million | $-44.06 Million | -0.466x | -320.10% |
| 2020-12-31 | $139.05 Million | $-15.42 Million | -0.111x | +51.63% |
| 2019-12-31 | $153.61 Million | $-35.21 Million | -0.229x | +34.41% |
| 2018-12-31 | $72.12 Million | $-25.20 Million | -0.349x | +55.14% |
| 2017-12-31 | $30.93 Million | $-24.10 Million | -0.779x | -6.06% |
| 2016-12-31 | $53.23 Million | $-39.10 Million | -0.734x | -143.23% |
| 2015-12-31 | $114.90 Million | $-34.70 Million | -0.302x | -100.77% |
| 2014-12-31 | $150.42 Million | $-22.62 Million | -0.150x | -818.07% |
| 2013-12-31 | $97.12 Million | $-1.59 Million | -0.016x | +90.57% |
| 2012-12-31 | $100.66 Million | $-17.48 Million | -0.174x | +43.68% |
| 2011-12-31 | $56.90 Million | $-17.54 Million | -0.308x | -606.80% |
| 2010-12-31 | $-189.17 Million | $-11.51 Million | 0.061x | -45.87% |
| 2009-12-31 | $-173.62 Million | $-19.51 Million | 0.112x | -38.04% |
| 2008-12-31 | $-158.34 Million | $-28.72 Million | 0.181x | +8.64% |
| 2007-12-31 | $-130.33 Million | $-21.76 Million | 0.167x | -20.53% |
| 2006-12-31 | $-106.17 Million | $-22.31 Million | 0.210x | -- |
About Standard Biotools Inc
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consum… Read more